Co-Pay Savings Offer

Eligible patients may pay as little as $0 on
their first RX and no more than $20 per RX until 12/31/2017*. [cash paying patients will likely pay more] [cash paying patients will likely pay more]

Two simple ways for caregivers and parents to enroll:

Text Message

Text "Enroll" to 37500 to receive an
eCard via text message

Benefits of enrolling via text
  • eCard sent directly to mobile phone
  • Real-time prescription status alerts
  • Program updates
 

Sign up Online

Click below to enroll online and get
the savings card.

*With the DYANAVEL® XR (amphetamine) Savings Card, eligible commercially insured and cash-paying patients can lower their out-of-pocket costs for DYANAVEL® XR prescriptions. After activation, insured patients may pay no more than $0 for their first prescription, and the card pays up to the maximum benefit. On subsequent uses, patients may pay no more than $20, and the card pays up to the maximum benefit. Cash-paying patients are responsible for the first $40, and the card pays up to the maximum benefit. Program benefit calculated on FDA approved dosing. Offer valid for up to 12 uses within the 2017 calendar year. A valid Prescriber ID# is required on the prescription. This program is valid from 1/1/2017 through 12/31/2017.

Patients with questions about the DYANAVEL® XR Savings offer should call 844-865-8684.

This Co-pay Savings Card is not health insurance. The Co-pay Savings Card is only accepted at participating pharmacies. For any questions, please call 844-865-8684. No membership fees required.

This offer is valid in the United States. Offer not valid for prescriptions reimbursed in whole or in part under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, the patient cannot use this offer.

Msg & Data rates may apply

 
 
 
 

IMPORTANT SAFETY INFORMATION & INDICATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including DYANAVEL XR, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

DYANAVEL XR is contraindicated
In patients known to be hypersensitive to amphetamine, or other components of DYANAVEL XR. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported
During treatment with monoamine oxidase inhibitors (MAOIs) and within 14 days following discontinuation of treatment with an MAOI because of the risk of hypertensive crisis
Prior to and during treatment assess for the presence of cardiac disease. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulant treatment at recommended doses. Sudden death has been reported in children and adolescents with structural cardiac abnormalities and other serious heart problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during DYANAVEL XR treatment.
CNS stimulants can cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
CNS stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychiatric illness. Prior to treatment, assess for the presence of bipolar disorder.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD. Monitor weight and height in children during treatment with DYANAVEL XR. Treatment may need to be interrupted in children not growing as expected.
CNS stimulants, including DYANAVEL XR, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants.
Serotonin syndrome risk is increased when amphetamines are co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue all serotonergic agents and initiate supportive treatment.
Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia. There is limited experience with DYANAVEL XR in controlled trials. Based on this limited experience, the adverse reaction profile of DYANAVEL XR appears similar to other amphetamine extended-release products. The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6–12 years) were: epistaxis (DYANAVEL XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
DYANAVEL XR use during pregnancy may cause fetal harm.
Breastfeeding is not recommended during treatment with DYANAVEL XR.
INDICATION

DYANAVEL® XR (amphetamine) extended-release oral suspension is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Please click here for Full Prescribing Information, including Boxed Warning regarding potential for Abuse and Dependence, and Medication Guide.

REFERENCES
1.
DYANAVEL XR [Prescribing Information]. Monmouth Junction, NJ: Tris Pharma Inc.; 2015.
2.
Data on File, FP102-0024, Tris Pharma Inc.
3.
Data on File, FP102-0001, Tris Pharma Inc.

You are now leaving dyanavelxrpro.com

Links to all outside Web sites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by Tris Pharma, Inc. Tris Pharma, Inc. accepts no responsibility or liability for the content or services of other Web sites.

+ EXPAND
X  CLOSE

IMPORTANT SAFETY INFORMATION & INDICATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including DYANAVEL XR, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

DYANAVEL XR is contraindicated
In patients known to be hypersensitive to amphetamine, or other components of DYANAVEL XR. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported
During treatment with monoamine oxidase inhibitors (MAOIs) and within 14 days following discontinuation of treatment with an MAOI because of the risk of hypertensive crisis
Prior to and during treatment assess for the presence of cardiac disease. Sudden death, stroke and myocardial infarction have been reported in adults with CNS stimulant treatment at recommended doses. Sudden death has been reported in children and adolescents with structural cardiac abnormalities and other serious heart problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during DYANAVEL XR treatment.
CNS stimulants can cause increases in blood pressure (mean increase about 2-4 mm Hg) and heart rate (mean increase about 3-6 bpm). Monitor all patients for tachycardia and hypertension.
CNS stimulants may cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychiatric illness. Prior to treatment, assess for the presence of bipolar disorder.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD. Monitor weight and height in children during treatment with DYANAVEL XR. Treatment may need to be interrupted in children not growing as expected.
CNS stimulants, including DYANAVEL XR, are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants.
Serotonin syndrome risk is increased when amphetamines are co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue all serotonergic agents and initiate supportive treatment.
Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia. There is limited experience with DYANAVEL XR in controlled trials. Based on this limited experience, the adverse reaction profile of DYANAVEL XR appears similar to other amphetamine extended-release products. The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6–12 years) were: epistaxis (DYANAVEL XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
DYANAVEL XR use during pregnancy may cause fetal harm.
Breastfeeding is not recommended during treatment with DYANAVEL XR.
INDICATION

DYANAVEL® XR (amphetamine) extended-release oral suspension is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Please click here for Full Prescribing Information, including Boxed Warning regarding potential for Abuse and Dependence, and Medication Guide.

REFERENCES
1.
DYANAVEL XR [Prescribing Information]. Monmouth Junction, NJ: Tris Pharma Inc.; 2015.
2.
Data on File, FP102-0024, Tris Pharma Inc.
3.
Data on File, FP102-0001, Tris Pharma Inc.